Market Overview

Cerus Announces Deal with Swiss Red Cross for Initial Deployment of INTERCEPT Blood System

Related CERS
Cerus Submits the Medical Device License Application to Health Canada for INTERCEPT Plasma
Partnership to Initiate Development of Whole Blood Pathogen Inactivation for Sub-Saharan Africa

Cerus Corporation (NASDAQ: CERS) announced today that it has signed a two-year purchase agreement with two regional Swiss Red Cross Blood Services for deployment of the INTERCEPT Blood System for plasma in Lausanne and Zurich. These two pilot centers supply an estimated 15,000 plasma units annually.

Posted-In: News

 

Most Popular

Related Articles (CERS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free